Kiora must secure financing to fund the planned Phase 3 CRAO and Phase 2b NAION trials. The company's $10M market cap and lack of disclosed revenue raise execution risk. Monitor for capital raise announcements and regulatory alignment discussions with the FDA.
Price Chart
Executive Summary
Kiora Pharmaceuticals in-licensed exclusive rights (outside Asia) to KIO-401 (mitucapistat), an oral calpain inhibitor that completed Phase 2 and Phase 3 studies in Japan for central retinal artery occlusion (CRAO). Kiora will pay Senju a $3.5M upfront payment, a low-teen-million technology transfer milestone (expected 2027), up to $168.5M in regulatory and commercial milestones, and single-digit royalties. The company plans a multinational Phase 3 CRAO trial (initiation targeted 2027) and a Phase 2b NAION trial (targeted 2028), subject to financing. Kiora also discontinued its KIO-104 program to prioritize KIO-401 and partnered KIO-301.
Key Financial Metrics
Key Facts
- Kiora obtained exclusive rights outside Asia to KIO-401, a late-stage oral calpain inhibitor for CRAO and NAION.
- Upfront payment of $3.5 million; technology transfer milestone of $12.5 million (low teen millions); up to $168.5 million in additional regulatory and commercial milestones.
- Senju completed Phase 2a (p=0.0398) and Phase 3 (p=0.0949 overall; p=0.0195 in legally blind subgroup) studies in Japan showing visual acuity improvement.
- Kiora plans to initiate a multinational Phase 3 CRAO trial in 2027 and a Phase 2b NAION trial in 2028, subject to funding.
- Kiora discontinued KIO-104 development to prioritize KIO-401 and partnered KIO-301.
- Company is evaluating financing alternatives to fund KIO-401 development; market cap is $10M.
Financial Impact
Upfront $3.5M + $12.5M technology transfer milestone + up to $168.5M in regulatory/commercial milestones + single-digit royalties on net sales outside Asia.
Risk Factors
- Kiora has a $10M market cap and must raise capital to fund late-stage trials; no revenue disclosed.
- Phase 3 CRAO trial results may not replicate Japanese data in a multinational setting.
- NAION Phase 2b trial is early-stage and carries development risk.
- Discontinuation of KIO-104 narrows pipeline to two assets.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001372514-26-000088 |
| Exhibit: ex992-companypresentatio.htm | 0001372514-26-000088 |
| Exhibit: ex991-pressreleasesenjulic.htm | 0001372514-26-000088 |
| Document: kprx-20261023.htm | 0001372514-26-000088 |
| Document: 0001372514-26-000088-index-headers.html | 0001372514-26-000088 |
| Document: 0001372514-26-000088-index.html | 0001372514-26-000088 |
| Document: 0001372514-26-000088.txt | 0001372514-26-000088 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 29, 2026 3d ago | 8-K | $1.76 $1.56 | ▼ −11.36% | ▼ −9.59% | $1.56 (−11.36%) |
Sep 8, 2026 7w ago | 8-K | $2.51 $2.49 | ▼ −0.80% | ▼ −0.33% | $1.56 (−37.85%) |
Aug 19, 2026 10w ago | 8-K | $2.60 $2.62 | ▲ +0.77% | ▲ +1.61% | $1.56 (−40.00%) |
Aug 7, 2026 12w ago | 8-K | $2.64 $2.58 | ▼ −2.27% | ▼ −2.24% | $1.56 (−40.91%) |
Jun 18, 2026 19w ago | 8-K | $2.53 $2.47 | ▼ −2.37% | ▼ −2.06% | $1.56 (−38.34%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers